PRIMARY STUDY
Circulating Endocannabinoids and Mortality in Hemodialysis Patients.
Key Findings: In patients with end-stage renal disease (ESRD) undergoing maintenance hemodialysis (MHD), levels of 2-arachidonoyl-sn-glycerol (2-AG) were positively correlated with body mass index, serum triglycerides, and body anthropometric measures, and a reduced risk of all-cause mortality. Anandamide (AEA) levels were negatively associated with very low-density lipoprotein but positively associated with interleukin-6.
Type of Study: Clinical Trial
Study Sample Size: 836
Study Result: Positive
Research Location(s): United States
Year of Pub: 2020
Cannabinoids Studied: Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG)
Phytocannabinoid Source: Not Applicable
Citation: Moradi H, Park C, Streja E, Argueta DA, DiPatrizio NV, You AS, Rhee CM, Vaziri ND, Kalantar-Zadeh K, Piomelli D. Circulating Endocannabinoids and Mortality in Hemodialysis Patients. Am J Nephrol. 2020;51(2):86-95. doi: 10.1159/000505444. Epub 2020 Jan 14. PMID: 31935741; PMCID: PMC7158229.
